SPRB (sprucebiosciences.com) Market Value to Book Value Ratio

Official company branding of sprucebiosciences.com (SPRB)

The resilience of Spruce Biosciences (SPRB) is based on inelastic demand and the unique mechanism of the drug tildacerfon. The market-to-book ratio visualizes investor confidence, with the indicator fixed at 1.45. The model relies on full production outsourcing for flexibility, although catalysts for asset revaluation following past R&D failures are still in the formation stage.

SPRB Spruce Biosciences Inc.: Market Value to Book Value in the range 07/04/2022 - 10/27/2026

Financial and market metric breakdowns for Spruce Biosciences Inc. (SPRB)

- price and consensus price forecast:
Stock Price Spruce Biosciences, Inc.|SPRB - Price Target Chart
- market capitalization data:
Market Value Spruce Biosciences|SPRB - Full Business Value
- book capitalization data:
Book Value per Share Spruce Biosciences|SPRB - Accounting Value of Company|Market Capitalization to Book Value Ratio sprucebiosciences.com|SPRB - Company Total Assets
- debt and liquidity data:
Debt to Equity Spruce Biosciences|SPRB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences|SPRB - Company Total Debt|Debts to Book Capitalization Spruce Biosciences
Initial company analysis:Spruce Biosciences, Inc. - SPRB
Original product of Spruce Biosciences

The metric is calculated as the quotient of the current market value of all shares divided by the total net assets. This multiplier determines the premium the market is willing to pay over the business's tangible capital. For Spruce Biosciences (SPRB), this valuation reflects the future commercialization potential of drugs targeting endocrine pathologies. Analyzing the price-to-book ratio allows for the identification of an overbought asset. The price action of this price-to-book ratio signals the degree of speculative risk.

Main competitors

Ascendis Pharma A/S (ASND) - Market Capitalization to Book Value Ratio|MDGL (madrigalpharma.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Metsera Therapeutics (MTSR)|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|crinetics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Market Value to Book Value|FOLD (Amicus Pharma) - Market Value to Book Value Ratio|89bio Pharma (ETNB) - Market Cap to Net Assets Ratio|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio structuretx.com (GPCR)|MiMedx (MDXG) - Market Cap to Net Assets Ratio|Market Value to Book Value RZLT (Rezolute Inc)|Lexicon Pharma - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio MBX Corp MBX|ALT (Altimmune, Inc.) - Market Capitalization to Book Value Ratio|aardvarktherapeutics.com (AARD) - Market-to-Book Ratio|SGMT - Market Cap to Net Assets Ratio|BioAge Labs (BIOA) - Market Cap to Book Value Multiple|BMEA (Biomea) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Quince|Market Capitalization to Book Value Ratio Fractyl Health, Inc. (GUTS)|Market Value to Book Value Ratio VTVT (vtvtherapeutics.com)|ATPC: Market Value to Book Value Ratio|Pluristem Therapeutics - Market-to-Book Ratio|SYBX - Market Value to Book Value Ratio|LPCN - Market Value to Book Value Ratio|matinasbiopharma.com - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio RDUS (Radius Pharmaceuticals)